Potential approval of a high value complex generic on the same lines as gRevlimid can be a positive surprise, adds the brokerage.

Revenue grew 11.4% to Rs 8,572 crore, but the bottom line of Rs 1,418 crore missed Bloomberg’s consensus estimate of Rs 1,514 crore.

The drugmaker plans to launch Semaglutide in 87 countries next year, including those where patents are expiring and emerging ...

Initially, Dr Reddy's will focus on launching the generic semaglutide in Canada, India, Brazil, Turkey, and other emerging ...

Q1 may have held steady, but the second half of FY26 will test Dr Reddy’s transition strategy. Without Revlimid, and with US pressure persisting, the Street will now watch execution timelines — not ...

The researchers first tested their hypothesis by delivering ODN directly to the hindbrain of rats. Once treated, the rats ...

When nurse practitioner Amy Rabon launched Sisterhood Sanctuary’s weight management program in 2019, 25 people signed up, ...

The study found that weight regain varied with follow-up, with participants experiencing weight regain at eight, 12, and 20 ...

The FDA has issued a warning as fake Ozempic have started circulating amid a recent trend seeing people using the diabetes ...

Dr. Reddy's Laboratories is closely monitoring a potential US tariff on the pharma sector, viewing it as both a risk and opportunity. The company plans a significant expansion with the generic version ...

Low doses of the injectable weight-loss medication semaglutide may improve symptoms of a hard-to-treat type of heart failure. This effect happened through direct action on the heart muscle and blood ...

Dr. Reddy's Laboratories intends to introduce a more affordable generic version of Novo Nordisk's popular weight-loss ...